key: cord-0798257-bitofnje
authors: Huang, Sheng-Wen; Tai, Ching-Hui; Hsu, Yin-Mei; Cheng, Dayna; Hung, Su-Jhen; Chai, Kit Man; Wang, Ya-Fang; Wang, Jen-Ren
title: Assessing the application of a pseudovirus system for emerging SARS-CoV-2 and re-emerging avian influenza virus H5 subtypes in vaccine development
date: 2020-06-06
journal: Biomed J
DOI: 10.1016/j.bj.2020.06.003
sha: cd0acf9e8f8a440346af06f904587dfb77826ac1
doc_id: 798257
cord_uid: bitofnje

Highly pathogenic emerging and re-emerging viruses continuously threaten lives worldwide. In order to provide prophylactic prevention from the emerging and re-emerging viruses, vaccine is suggested as the most efficient way to prevent individuals from the threat of viral infection. Nonetheless, the highly pathogenic viruses need to be handled in a high level of biosafety containment, which hinders vaccine development. To shorten the timeframe of vaccine development, the pseudovirus system has been widely applied to examine vaccine efficacy or immunogenicity in the emerging and re-emerging viruses. Here we developed pseudovirus systems for emerging SARS coronavirus 2 (SARS-CoV-2) and re-emerging avian influenza virus H5 subtypes which can be handled in the biosafety level 2 facility. Through the generated pseudovirus of SARS-CoV-2 and avian influenza virus H5 subtypes, we successfully established a neutralization assay to quantify the neutralizing activity of antisera against the viruses. In addition, the result of re-emerging avian influenza virus H5Nx pseudoviruses provided valuable information for antigenic evolution and immunogenicity analysis in vaccine candidate selection. Together, our study assessed the potency of pseudovirus systems in vaccine efficacy, antigenic analysis, and immunogenicity in the vaccine development of emerging and re-emerging viruses. Instead of handling live highly pathogenic viruses in a high biosafety level facility, using pseudovirus systems would speed up the process of vaccine development to provide community protection against emerging and re-emerging viral diseases with high pathogenicity.

others [5] . The advantages of using such a system is its rapid production, it is 53 quantifiable, and is relatively safe since progeny viruses can only undergo a single 54 replication cycle [6, 7] . In the lentivirus-vector system, although most of the vectors 55 are derived from human immunodeficiency virus type 1 (HIV-1), modified versions of 56 the lentivirus vector are non-pathogenic [8] . This is also the case in the VSV-ΔG 57 pseudovirus system. In this system, the VSV-ΔG vector lacks the G envelope protein 58 of VSV, thus allowing for recombination with a foreign envelope protein and/or 59 reporter gene. Establishment of pseudoviruses using the lentivirus-vector system have 60 been previously reported for emerging and re-emerging viruses that require BSL-3/4 61 facilities such as NiV To generate SARS-CoV or SARS-CoV-2 and avian influenza virus pseudovirus, 94 we applied the lentiviral vector system provided by National RNAi Core of Academic 95

Sinica Taiwan to produce the pseudoviruses expressing full-length S protein and 96 HA/NA proteins, respectively. For SARS-CoV or SARS-CoV-2 pseudovirus, the 97 sequences of S protein were de novo synthesized. Synthesized genes were cloned into 98 pMD.G plasmid to express SARS-CoV or SARS-CoV-2 pseudoviruses. For avian 99 influenza virus pseudovirus, HA and NA sequences from different avian influenza 100 viruses H5N2, H5N6, and H5N8 (H5Nx) were synthesized and replaced the VSV-G 101 envelope glycoprotein in pMD.G plasmid. Cloned plasmids were transformed into 102

One Shot Stbl3 Chemically Competent cell (Invitrogen) and were amplified in 103

Lysogeny Broth with 100 μg/ml ampicillin. Plasmids were extracted by Zymo 104

Research midi kit. The 293T cells were seeded at the concentration of 2x10 6 cells in 105 6-well plates at 37°C with 5% CO 2 for 24 hours, and then the cells were transfected 106 with 1 μg of pCMVdeltaR8.91, pLAS2w.RFP-C.Pneo and pMD.G plasmids (pMD.G 107 with S gene for SARS-CoV or SARS-CoV-2 tagged by HA on the C-terminus and 108 pMD.G with indicated HA and NA gene pairs for avian influenza virus, respectively) 109 by PolyJet reagent according to manufacturer's instructions (Fig. 1 ). In the following 

In following the generation of the pseudoviruses, we first focused on 212 group, and maximum % RFP achieved 31.05% referring to 3.85 x 10 6 TU/ml. Taken 227 together, the TU result implied similar pseudovirus production efficiency between 228 SARS-CoV and SARS-CoV-2 in our lentiviral pseudovirus system. 229

Early SARS coronavirus reports have shown that S1-S2 cleavage can be 230 enhanced by exogenous proteases, such as trypsin, thermolysin, and elastase [16, 39] . 231

Next, we examined whether exogenous trypsin increases the transduction efficiency 232 of our generated SARS-CoV and SARS-CoV-2 pseudovirus. We added exogenous 233 trypsin during SARS-CoV and SARS-CoV-2 pseudovirus absorption to Vero-E6 cells, 234 until we harvested cells for cytometry analysis. Unexpectedly, we observed a 235 reduction in virion transduction with trypsin presence, especially for SARS-CoV 236 virions. With trypsin treatment, the TU of SARS-CoV virions decreased 93% from 9.5 237

x 10 5 to 6.5 x 10 4 TU/ml. In contrast to dramatic TU reduction of SARS-CoV virions, 238 the TU of SARS-CoV-2 moderately reduced 43% from 1.09 x10 6 to 6.2 x 10 5 TU/ml 239 (Fig. 4b) . The transduction reduction effects of exogenous trypsin presence since 

After successfully establishing emerging virus SARS-CoV-2 pseudovirus 281 transduction and neutralization assays, we next investigated the generated 282 pseudovirions of re-emerging virus avian influenza virus H5Nx. In contrast to using influenza H5Nx subtypes showed similar transduction unit (TU) within 10 6 to 10 8 290 TU/ml in MDCK cells (Fig. 3c) although the diverse TUs were seen among the 291 subtypes. We thus successfully transduced pseudovirions of re-emerging avian 292

We next examined the applicability of avian influenza virus H5Nx pseudovirus 294 in neutralization assay. Contrast to single type of SARS-CoV-2 due to only one 295 dominant strain, various avian influenza virus subtypes co-circulated in worldwide. 296

Taiwan and worldwide, including H5N2, H5N6, and H5N8 subtypes to determine the 298 neutralization antibody by using H5Nx pseudovirus. Instead of raising antibody by 299 structural protein expressing recombinant protein subunit vaccine in SARS-CoV-2 300 virus, we concentrated the inactivated avian influenza pseudovirus as immunogens to 301 raise antisera against avian influenza HA and NA structural proteins in mice. We 302 determined neutralization antibody titers of raised antisera against different subtypes 303 of influenza virus and generated an antigenic map to analyze the similarity of 304 antigenicity according to neutralization antibody titers. Mouse antisera were 305 respectively generated by each selected strain and examined neutralization activities 306 against all selected avian influenza pseudovirions. Neutralization titers demonstrated 307 that avian influenza virus exhibited partial cross-reactivity among H5N2, H5N6, and 308 H5N8 subtypes. High neutralization titers of antisera between 1:160 and ≧1:5120 309

were observed among examined subtypes ( Although on average high neutralization titers were generally seen among the antisera 316 against diverse subtype pseudovirus, we still observed the 2 to 8-folds of different 317 titers among examined pseudovirions as which were neutralized by each antiserum. 

Emerging and Reemerging Human Viral 480 Diseases

Evidence for positive 482 selection in foot-and-mouth disease virus capsid genes from field isolates

Whole-genome analysis of human influenza A virus reveals multiple persistent 486 lineages and reassortment among recent H3N2 viruses

Recombination strategies and evolutionary dynamics of the Human 490 enterovirus A global gene pool

Development and Applications of VSV 493 Vectors Based on Cell Tropism

Influenza M2 envelope 495 protein augments avian influenza hemagglutinin pseudotyping of lentiviral 496 vectors

498 Establishment of retroviral pseudotypes with influenza hemagglutinins from 499 H1, H3, and H5 subtypes for sensitive and specific detection of neutralizing 500 antibodies

Targeted 502 Lentiviral Vectors: Current Applications and Future Potential. Gene Therapy -503 Tools and Potential Applications. IntechOpen

Nipah pseudovirus system 505 enables evaluation of vaccines in vitro and in vivo using non-BSL-4 facilities

A bioluminescent imaging 508 mouse model for Marburg virus based on a pseudovirus system

Glycoproteins Pseudotype with Lentiviral Vectors and Reveal a Broad 512 Spectrum of Cellular Tropism

Characterization of spike 514 glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity 515 with SARS-CoV

Receptor 517 Variation and Susceptibility to Middle East Respiratory Syndrome 518

A safe and convenient 520 pseudovirus-based inhibition assay to detect neutralizing antibodies and screen 521 for viral entry inhibitors against the novel human coronavirus MERS-CoV

Vesicular stomatitis virus pseudotyped with severe acute respiratory syndrome 525 coronavirus spike protein

527 Characterization of severe acute respiratory syndrome-associated coronavirus 528 (SARS-CoV) spike glycoprotein-mediated viral entry

A 531 system for functional analysis of Ebola virus glycoprotein

Lyophilisation of influenza, 534 rabies and Marburg lentiviral pseudotype viruses for the development and 535 distribution of a neutralisation -assay-based diagnostic kit

An LASV GPC 538 pseudotyped virus based reporter system enables evaluation of vaccines in 539 mice under non-BSL-4 conditions

Activation of influenza A viruses by 541 trypsin treatment

Cell Tropism of Influenza Virus Mediated 543 by Hemagglutinin Activation at the Stage of Virus Entry

Role of Hemagglutinin Cleavage for the Pathogenicity of 546 Influenza Virus

Hemagglutinin Cleavage Site Control the Virulence of a Neurotropic H1N1 549 Influenza Virus

Activation of the SARS coronavirus 551 spike protein via sequential proteolytic cleavage at two distinct sites

Cyclic Lipopeptide Disrupts Viral Infectivity

Furin cleavage of the SARS coronavirus spike 557 glycoprotein enhances cell-cell fusion but does not affect virion entry

Host cell proteases: Critical determinants of 560 coronavirus tropism and pathogenesis

Longitudinally profiling neutralizing antibody response to SARS 563 coronavirus with pseudotypes

Development and 565 optimization of a sensitive pseudovirus-based assay for HIV-1 neutralizing 566 antibodies detection using A3R5 cells

Establishment and validation 569 of a pseudovirus neutralization assay for SARS-CoV-2. Emerging Microbes & 570

Development of a safe 572 and convenient neutralization assay for rapid screening of influenza 573 HA-specific neutralizing monoclonal antibodies

Development and 576 Evaluation of a Pseudovirus-Luciferase Assay for Rapid and Quantitative 577 Detection of Neutralizing Antibodies against Enterovirus 71

Mouse's Susceptibility to Infection by Authentic and Pseudotyped MERS-CoV

A 583 recombinant vesicular stomatitis-based Lassa fever vaccine elicits rapid and 584 long-term protection from lethal Lassa virus infection in guinea pigs

Efficacy and effectiveness of an rVSV-vectored vaccine 588 expressing Ebola surface glycoprotein: interim results from the Guinea ring 589 vaccination cluster-randomised trial

HIV-1 pseudoviruses constructed in China 591 regulatory laboratory

593 A Pseudovirus System for the Testing of Antiviral Activity of Compounds in 594 Different Cell Lines

Production of lentiviral vectors for 596 transducing cells from the central nervous system

Protease-mediated enhancement of severe acute respiratory syndrome 600 coronavirus infection

Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Antigenic 605 Drift of the Influenza A(H1N1)pdm09 Virus Neuraminidase Results in 606

Reemergence of enterovirus 71 in 2008 in taiwan: dynamics of genetic and 610 antigenic evolution from 1998 to

Mapping Enterovirus A71 Antigenic Determinants from Viral Evolution

Dengue viruses cluster antigenically but not as discrete 616 serotypes

Substitutions Near the Receptor Binding Site Determine Major Antigenic 619 Change During Influenza Virus Evolution

Mapping the Antigenic and Genetic Evolution of 622 Influenza Virus

Table 1. Neutralization assay result of SARS-CoV-2 mouse antisera by pseudovirus virus control (mean)

Table 2. Cross-neutralization assay result of avian influenza virus H5Nx by

Lenti-H5N8